Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID 2: Certolizumab Pegol + MTX in RA
NCT00160602Phase 3Completed
- Sponsor
- UCB
- Start
- Jun 2005
- Primary completion
- Sep 2006
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of certolizumab pegol in rheumatoid arthritis (RA) (3 arms), sponsored by UCB. Primary endpoint: American College of Rheumatology 20% Improvement at 24 weeks. Started Jun 2005; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00160602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00160602.